Filter by: Subject

Filter by: Subject

Results Per Page:

Positron emission tomography/computed tomography (PET/CT) (4)
Prostate-specific membrane antigen (PSMA) (4)
Patients (3)
Positron emission tomography (PET) (3)
Prostate cancer (3)
South Africa (SA) (3)
Tuberculosis (TB) (3)
177Lu-PSMA (2)
68Ga-PSMA (2)
PET/CT (2)
Prostate carcinoma (2)
18F-FDG PET/CT (1)
18F-fluorodeoxyglucose (18F-FDG) (1)
68Ga-citrate (1)
68Ga-citrate PET/CT (1)
68Ga-DKFZ-PSMA-11 (1)
68Ga-HBED-CC-(Ahx)Lys-NH-CO-NH-Glu (1)
68Ga-PSMA PET/CT (1)
68Ga-PSMAHBED (1)
Actinium-225 (1)
Black South-African (BSAs) (1)
Breast cancer (1)
Breast uptake (1)
Burkitt lymphoma (BL) (1)
Cavernous sinus syndrome (1)
Chemotherapy-naïve (1)
Computed tomography (CT) (1)
Computerized tomography (CT) (1)
Endoradiotherapy (1)
Fluorine-18 2-fluoro-2-deoxyglucose (18F-FDG) (1)
Fluorine-18 fluorodeoxyglucose (1)
Fluorine-18-fluorodeoxyglucose (18F-FDG) (1)
Imaging technology (1)
Lung lesions (1)
Menstrual cycle (1)
Metastasized castration-resistant prostate cancer (mCRPC) (1)
Metastatic castrate-resistant prostate cancer (1)
Metastatic castration-resistant prostate cancer (mCRPC) (1)
Morbidity (1)
Mortality (1)
Neuroendocrine tumour (NET) (1)
Patient management (1)
Patient treatment (1)
Peptide receptor radionuclide therapy (PRRT) (1)
PET/computed tomography (1)
Positron emission tomography/computed tomography (PET/CT) (1)
Primary prostate carcinoma (PPC) (1)
Prostate-specific antigen (PSA) (1)
Prostate-specific membrane antigen radioligand therapy (PSMA-RLT) (1)
Racial differences (1)
Radioligand therapy (1)
Receptor radioligand therapy (RLT) (1)
Somatostatin receptors (1)
Superscan (1)
Theranostics (1)
Treatment (1)
White South-African (WSAs) (1)